Education
About Us
Working with TipRanks
Follow Us
The United Laboratories International Holdings Limited (HK:3933)
:3933
RESEARCH TOOLSreports
3933 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$8.20 - HK$17.98
Previous CloseN/A
Volume6.42M
Average Volume (3M)21.82M
Market Cap
$30.27B
Enterprise ValueHK$22.22B
Total Cash (Recent Filing)$6.33B
Total Debt (Recent Filing)$3.16B
Price to Earnings (P/E)8.4
Beta0.80
Next Earnings
Mar 31, 2026EPS Estimate
0.37Next Dividend Ex-Date
Sep 25, 2025Dividend Yield3.59%
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,973,026,500
10 Day Avg. Volume23,651,301
30 Day Avg. Volume21,821,185
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda6.63
Forecast
1Y Price Target
$16.51Price Target Upside-0.89% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$8.20 and its highest was HK$17.98 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is $30.27B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Mar 31, 2026 which is in 210 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Aug 28, 2025. The company reported HK$1.14 earnings per share for the quarter, missing the consensus estimate of HK$1.454 by -HK$0.314.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Overvalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.175 which represents an annual dividend yield of 3.59%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.37.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$1.14 in its last earnings report, missing expectations of HK$1.454. Following the earnings report the stock price went down -4.783%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.51 (-0.89% Downside)
$16.51 (-0.89% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.18%
12-Months-Change
Fundamentals
Return on Equity
21.02%
Trailing 12-Months
Asset Growth
30.76%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
3.82%
Mutual Funds
0.08% Other Institutional Investors
93.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---